Co-trafficking of HFE, a Nonclassical Major Histocompatibility Complex Class I Protein, with the Transferrin Receptor Implies a Role in Intracellular Iron Regulation*

Cindy N. GrossDagger §, Alivelu Irrinki, John N. Feder, and Caroline A. EnnsDagger parallel

From the Dagger  Department of Cell and Developmental Biology, Oregon Health Sciences University, Portland, Oregon 97201-3098 and  Progenitor Inc., Menlo Park, California 94025

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The mechanism by which a novel major histocompatibility complex class I protein, HFE, regulates iron uptake into the body is not known. HFE is the product of the gene that is mutated in >80% of hereditary hemochromatosis patients. It was recently found to coprecipitate with the transferrin receptor (Feder, J. N., Penny, D. M., Irrinki, A., Lee, V. K., Lebron, J. A., Watson, N., Tsuchihashi, Z., Sigal, E., Bjorkman, P. J., and Schatzman, R. C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1472-1477; Parkkila, S., Waheed, A., Britton, R. S., Bacon, B. R., Zhou, X. Y., Tomatsu, S., Fleming, R.E., and Sly, W. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13198-13202) and to decrease the affinity of transferrin for the transferrin receptor (Feder et al.). In this study, HeLa cells were transfected with HFE under the control of the tetracycline-repressible promoter. We demonstrate that HFE and the transferrin receptor are capable of associating with each other within 30 min of their synthesis with pulse-chase experiments. HFE and the transferrin receptor co-immunoprecipitate throughout the biosynthetic pathway. Excess HFE is rapidly degraded, whereas the HFE-transferrin receptor complex is stable. Immunofluorescence experiments indicate that they also endocytose into transferrin-positive compartments. Combined, these results suggest a role for the transferrin receptor in HFE trafficking. Cells expressing HFE have modestly increased levels of transferrin receptor and drastically reduced levels of ferritin. These results implicate HFE further in the modulation of iron levels in the cell.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Hereditary hemochromatosis is an autosomal recessive disease more common in people of Northern European descent than cystic fibrosis, phenylketonuria, and muscular dystrophy combined (1). It is characterized by massive iron overload of the parenchymal tissue of many organs, including the liver, pancreas, heart, and pituitary. Siderosis and cirrhosis of these organs cause liver failure, diabetes mellitus, cardiac arrhythmia, hypogonadism, and other complications leading to premature death (2-4). Over 80% of hereditary hemochromatosis patients have the same mutation in the HFE gene (5).

Positional cloning of HFE from the HLA-linked region of chromosome 6p and its subsequent crystallization (6) have revealed its significant sequence and structural homology (37% identity in the ectodomain) to MHC1 class I proteins. MHC class I molecules are normally involved in antigen peptide presentation. HFE has not been found to bind such peptides. Its crystal structure suggests that the ancestral peptide-binding groove is too narrow for such a function (6). Emerging results suggest that the functional role of HFE may lie in its interaction with the transferrin receptor (TfR) (6-8). HFE is therefore described as a nonclassical MHC class I molecule. MHC class I molecules are capable of functions outside of antigen presentation. Some have been shown to interact with receptors such as the insulin receptor and the epidermal growth factor receptor (9-13). Antibodies against these MHC class I proteins decrease surface binding of insulin or the epidermal growth factor to their respective receptors, suggesting that these MHC class I proteins are involved in the formation of high affinity ligand-binding sites. The neonatal Fc receptor is a nonclassical MHC class I molecule that acts as an antibody transporter. The current model of neonatal Fc receptor function proposes binding of ligand at acidic pH and transport in acidic vesicles through the epithelial monolayer. Further evidence suggests the involvement of the neonatal Fc receptor in IgG homeostasis in the serum (for review, see Ref. 14). Likewise, HFE may be involved in regulated transport of molecules associated with iron homeostasis.

The molecular evidence concerning HFE mediation of iron homeostasis has been converging on its close association with TFR. Northern blot analysis indicated that HFE is widely distributed throughout the body, with more abundant message levels in organs that are major sites of iron metabolism, namely the liver and intestine (5). Its unique pattern of protein expression in the gastrointestinal tract (specifically in the crypt cells of the ileum, the putative site of iron absorption in the intestine (15)) suggests a role for HFE in the sensing of bodily iron levels and the regulation of transport of iron across epithelial layers. HFE expression in the basolateral membrane of the intestinal epithelia and the identification of HFE in the placenta (7) are indicative of a more general association with TfR in regulating iron transport across epithelial barriers. It has long been suspected that individuals with hereditary hemochromatosis have a defect in the transport of iron across the mucosal barrier, i.e. transport into the blood rather than uptake from the lumen (4). The perinuclear staining of HFE in proliferating crypt cells is indicative of co-localization with recycling receptors, such as TfR (16), rather than with the hypothesized iron transporter on the apical surface of these cells. The regulatory influence of HFE on iron transport may therefore be either in internal cellular compartments or at the basolateral cell surface.

More specific evidence for the interaction of HFE with TfR is demonstrated by the co-immunoprecipitation of HFE with TfR (7, 8) and more significantly by the ability of HFE to increase the dissociation constant of transferrin (Tf) with TfR (6, 8). The association of HFE with TfR and its yet to be defined role in iron regulation led us to investigate more closely its trafficking in the cell. For this study, we have expressed a FLAG epitope-tagged HFE (fHFE) under the control of the tetracycline-repressible promoter. This system allows us to tightly regulate the expression level of fHFE within the same stable cell line. The results of this study demonstrate that cells expressing HFE have decreased ferritin levels and increased TfR number, implying low intracellular iron levels. We also demonstrate that HFE is able to associate with TfR within 30 min of its synthesis and can associate with TfR in both the biosynthetic and metabolic pathways. HFE pools that are not associated with TfR are rapidly degraded. Immunofluorescent detection of fHFE in HeLa cells indicates that it co-localizes with TfR and Tf on the cell surface and in intracellular compartments. Localization of HFE on the cell surface and in endocytic compartments implicates HFE in the regulation of iron uptake, especially in light of indirect evidence suggesting that cells expressing HFE have decreased intracellular iron stores.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Plasmids-- The plasmid pcDNA3.1+ containing HFE cDNA clone 24 fused to the octapeptide FLAG sequence (Progenitor Inc.) has been previously described (17). The tetracycline-repressible plasmid pUHD10-3 was a kind gift from Drs. M. Gossen and H. Bujard (Zentrum fur Molekulare Biologies, Universitat Heidelberg) (18).

Subcloning-- The HFE coding sequence is contained within an ~3.0-kilobase NheI/XbaI fragment, which was subsequently cloned into the XbaI site of pUHD10-3, resulting in the fWTHFE/pUHD10-3 construct.

Cell Culture-- HeLa cells transfected with the tetracycline-transactivable plasmid pUHD15-1 were a gift from Dr. Sandra L. Schmid (Scripps Research Institute). They were cotransfected with the fWTHFE/pUHD10-3 plasmid and the pBSpac plasmid containing the puromycin resistance gene (12) using LipofectAMINE (Life Technologies, Inc.) according to the manufacturer's directions. Colonies selected with puromycin (200 ng/ml) and recloned to ensure a pure cell line were screened by SDS-PAGE and Western blotting for expression of HFE using the 1868 rabbit anti-FLAG (19) and CT1 rabbit anti-HFE (17) antibodies. The clone used for these experiments is named fWTHFE/tTA HeLa. The resulting fWTHFE/tTA HeLa cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 400 µg/ml G418 (Geneticin, Calbiochem), and 200 ng/ml puromycin, with (tet+) or without (tet-) 2 µg/ml tetracycline.

Iodination-- Human holotransferrin was labeled with Na125I using lactoperoxidase and used for Scatchard analysis as described previously (19).

Immunoprecipitation-- fWTHFE/tTA HeLa cells were washed three times with 2 ml of PBS (pH 7.4) and lysed with NET-Triton (150 mM NaCl, 5 mM EDTA, and 10 mM Tris (pH 7.4) with 1% Triton X-100). Cell lysates were preadsorbed for at least 45 min at 4 °C with 50 µl of Pansorbin (Calbiochem) per ~106 cells to reduce precipitation of nonspecific protein. Preadsorbed lysates were incubated for at least 45 min at 4 °C with 30 µl of rabbit anti-mouse antibody (Miles Scientific)-coated Pansorbin and 2 µg of either mouse anti-FLAG antibody (M2, Eastman Kodak Co.) or mouse anti-transferrin receptor antibody (4091 and 4093, gifts from Vonnie Landt, Washington University, St. Louis, MO) or with 50 µl of Pansorbin and 3 µl of sheep anti-hTfR serum per ~106 cells. The Pansorbin pellet was resuspended in 200 µl of NET/Triton and washed through 1 ml of radioimmune precipitation assay buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS, 50 mM Tris, 150 mM NaCl, and 0.2% sodium azide) with 15% sucrose. Samples were eluted in 100 µl of 2× Laemmli buffer (125 mM Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, and 10% 2-mercaptoethanol) (20) with 10% 2-mercaptoethanol and subjected to SDS-PAGE analysis on a 10% denaturing acrylamide gel.

Pulse-Chase Experiments-- Uninduced (tet+) and induced (tet-) subconfluent fWTHFE/tTA HeLa cells in 35-mm dishes were washed three times with sterile PBS (pH 7.4) and preincubated for 15 min at 37 °C in RPMI 1640 medium minus methionine (RPMI-Met medium; Life Technologies, Inc.) prior to labeling. Cells were pulsed for 10 min at various time points with 100 µCi or incubated overnight with 10 µCi of [35S]methionine in RPMI-Met medium with 10% fetal bovine serum. The cells were then washed three times with PBS and chased at 30-min intervals between 0 and 120 min with complete medium. At the indicated times, cells were lysed for 5 min on ice in NET-Triton. Cell extracts were subjected to immunoprecipitation with M2 or 4093 antibody as described above and analyzed by SDS-PAGE on a 10% denaturing acrylamide gel under reducing conditions. Gels were fixed, treated with Amplify (Amersham Pharmacia Biotech) for 30 min, dried, and subjected to PhosphorImager analysis (Molecular Dynamics, Inc.).

Endo-beta -N-acetylglucosaminidase H Treatment-- Immunoprecipitated pellets were resuspended in 90 µl of denaturing buffer (0.5% SDS and 1% 2-mercaptoethanol) and boiled for 10 min at 95 °C. The samples were iced, and 10 µl of 10× citrate buffer (500 mM sodium citrate (pH 5.5)) was added to the pellet. Samples were incubated for at least 2 h at 37 °C in the presence or absence of endo-beta -N-acetylglucosaminidase H (endo H; 8 units; New England Biolabs Inc.). Samples were eluted with 50 µl of 2× Laemmli buffer with 10% 2-mercaptoethanol and subjected to SDS-PAGE analysis on a 10% denaturing acrylamide gel. Gels were fixed, treated with Amplify, dried, and subjected to PhosphorImager analysis.

Half-life Experiments-- Subconfluent fWTHFE/tTA HeLa cells (tet+ and tet-) in 35-mm dishes were washed three times with sterile PBS (pH 7.4) and preincubated for 15 min at 37 °C in RPMI-Met medium prior to labeling. Cells were pulsed for 1 h at various time points with 100 µCi of [35S]methionine in RPMI-Met medium with 10% fetal bovine serum. The cells were washed three times with PBS and chased in 2-h increments from 0 to 8 h with complete medium. At the completion of the chase time point, all cells were lysed for 5 min on ice in NET-Triton. Cell extracts were subjected to immunoprecipitation with antibody M2 to immunoprecipitate HFE or with antibody 4091 to immunoprecipitate TfR as described above and analyzed by SDS-PAGE on a 10% denaturing acrylamide gel under reducing conditions. Gels were fixed, treated with Amplify, dried, and subjected to PhosphorImager analysis.

Western Immunodetection-- Cell extracts from ~3 × 105 cells were diluted with 4× Laemmli buffer, or immunoprecipitates were eluted with 2× Laemmli buffer and subjected to electrophoresis on SDS-10 or 12% polyacrylamide gels under reducing conditions. The proteins were transferred to nitrocellulose. Immunoblot analysis was performed using sheep anti-hTfR serum (1:10,000 dilution) (19), mouse anti-FLAG antibody M2 (1:20,00 dilution), and/or sheep anti-human ferritin antibody (1:100 dilution; The Binding Site, Ltd.) followed by the appropriate secondary antibody conjugated to horseradish peroxidase and chemiluminescence (SuperSignal, Pierce) per the manufacturer's directions.

Tunicamycin Treatments-- Subconfluent fWTHFE/tTA HeLa cells (tet+ and tet-) in 35-mm dishes were washed three times with sterile PBS (pH 7.4) and preincubated for 1 h at 37 °C with 5 µg/ml tunicamycin (Calbiochem) or mock-treated with Me2SO (final concentration of 0.05%). Cells were washed three times with sterile PBS (pH 7.4) and incubated overnight at 37 °C with complete medium. The next day, the cells were lysed for 5 min on ice in NET-Triton and subjected to immunoprecipitation with antibody M2 or sheep anti-hTfR serum as described above. Immunoprecipitates were eluted with 100 µl of 2× Laemmli buffer with 10% 2-mercaptoethanol and subjected to SDS-PAGE on a 10% denaturing acrylamide gel. Gels were subjected to Western blotting with monoclonal anti-transferrin receptor antibody (H68.4, Zymed Laboratories, Inc.) as described (19).

Tf-Agarose Precipitation-- Lysates of 106 tet+ or tet- fWTHFE/tTA HeLa cells were preadsorbed for 1 h at 4 °C with 100 µl of bovine serum albumin covalently linked to agarose (50% suspension in PBS). Supernatants were incubated for 1 h at 4 °C with 200 µl of transferrin covalently linked to agarose (50% suspension in PBS). The pellet was washed two times with NET-Triton and eluted twice with 75 µl of 2× Laemmli buffer with 10% 2-mercaptoethanol and subjected to SDS-PAGE on a 12% denaturing acrylamide gel as described above. Gels were transferred to nitrocellulose and subjected to Western blotting as described above.

PhosphorImager Quantitation-- IP Lab Gel 1.5 (Molecular Dynamics, Inc.) was used to quantitate images by determining the volume within a region of fixed pixel number at each band of interest within the gel. Bands were normalized for methionine numbers within the protein (10 for HFE and 14 for the TfR monomer).

Immunocytochemistry-- Subconfluent fWTHFE/tTA HeLa cells (tet+ and tet-) grown on coverslips were washed three times with 2 ml of PBS (pH 7.4) and, if applicable, incubated for 30 min at 37 °C with 4 µg/ml Texas Red-labeled Tf (Molecular Probes, Inc.) in Dulbecco's modified Eagle's medium with 20 mM HEPES (pH 7.4) and 2 mg/ml ovalbumin. All cells were washed three times with 2 ml of PBS, fixed for 15 min in 3% paraformaldehyde at room temperature, and washed an additional two times with PBS. Cells were blocked in 10% newborn calf serum in PBS with 0.5% Triton X-100 to permeabilize cells for at least 30 min at room temperature. The fixed cells were incubated for at least 1 h at room temperature in 1:50 diluted sheep anti-hTfR serum, 100 µg/ml anti-TfR antibody 4093, 25 µg/ml anti-FLAG antibody M2, 30 µg/ml anti-HFE antibody CT1, or 2 µg/ml anti-beta 2-microglobulin antibody (Immunotech International). Coverslips were then washed twice with PBS and incubated again for at least 1 h at room temperature with a 1:50 dilution of fluorescein isothiocyanate (FITC)-labeled swine anti-goat antibody (Tago, Inc.), FITC-labeled goat anti-mouse antibody (Tago, Inc.), or tetramethylrhodamine isothiocyanate-labeled anti-rabbit antibody (Cappel).

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Identification of a Clone That Expresses Epitope-tagged HFE under Control of the Tetracycline-regulated Promoter-- The tetracycline-responsive promoter system developed by Gossen and Bujard (18) was used to create a cell line in which HFE expression could be tightly controlled. tTA HeLa cells stably express a tetracycline-transactivable (tTA) fusion protein with the Escherichia coli tetracycline-responsive element (tetR)-binding domain and the VP16 activation domain from herpes simplex virus. In the absence of tetracycline, the fusion protein binds operator sequences upstream of the fWTHFE/pUHD10-3 multiple cloning region, promoting expression of fHFE. In the presence of tetracycline-supplemented (tet+) medium, the tTA fusion protein binds tetracycline and releases from the tetracycline-responsive promoter, preventing fHFE transcription. Fig. 1 shows fHFE, TfR, and ferritin (Ft) expression in fWTHFE/tTA HeLa cells that have been uninduced (tet +) or induced (tet-) for at least 10 days. Western blotting of lysates of 3 × 105 cells detected no fHFE (~43 kDa) in tet+ cells with anti-FLAG antibody M2. fHFE was easily detected in lysates of tet- cells. TfR (94 kDa) levels increased slightly (~50%) in cells expressing fHFE. A large decrease (>10-fold) in the levels of Ft (19 and 21 kDa) was seen in cells expressing fHFE. These results imply that overexpression of HFE reduces intracellular iron load. The iron regulatory protein modulates changes in TfR and Ft levels. At low intracellular iron concentrations, the iron regulatory protein binds to the iron response element stem loop structure in the 3'-untranslated portion of the TfR mRNA, stabilizing the message and thus increasing TfR numbers. The same reduction in intracellular iron load results in the binding of the iron regulatory protein to the 5'-untranslated stem loop of Ft mRNA, blocking translation and thus decreasing Ft levels.


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 1.   Inducible expression of fHFE in fWTHFE/tTA HeLa cells. Lysates of ~3 × 105 fWTHFE/tTA HeLa cells, uninduced (tet+) or induced (tet-) for fHFE expression, were run on a 12% denaturing acrylamide gel under reducing conditions. Proteins were transferred to nitrocellulose and detected with sheep anti-hTfR (1:10,000), mouse anti-FLAG (M2, 1:20,000), or sheep anti-ferritin (1:100) antibodies and the appropriate horseradish peroxidase-conjugated secondary antibody (1:10,000). Chemiluminescence detected ~94-, ~43-, and 19/21-kDa bands representing TfR, fHFE, and Ft, respectively. The increased TfR expression and decreased Ft expression in fHFE-expressing cells are indicative of a decrease in intracellular iron load. These results are representative of three experiments without significant variation between experiments.

HFE Lowers the Affinity of TfR for Tf in fWTHFE/tTA HeLa Cells-- Scatchard analysis of 125I-Tf surface binding to tet+ or tet- fWTHFE/tTA HeLa cells at 4 °C reflects the ability of HFE to modulate Tf binding to TfR (Fig. 2). The Kd of Tf and TfR increased from 1.2 to 11 nM Tf with expression of HFE, indicating that the affinity of Tf for TfR decreases when fHFE is overexpressed. The linearity of the slope rather than a biphasic slope of the Scatchard plot shows that fHFE sufficiently saturated TfR such that no high affinity binding sites were evident. These data also show that fHFE expression moderately increased the amount of Tf-binding sites (52%), in keeping with the increased expression of TfR on Western blots (Fig. 1).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 2.   fHFE lowers TfR affinity for Tf in fWTHFE/tTA HeLa cells. Scatchard analysis of Tf binding to 1.38 × 106 uninduced (tet+; open squares) or 1.17 × 106 induced (tet-; closed squares) fWTHFE/tTA HeLa cells shows elevation of the dissociation constant from 1.2 to 11 nM Tf when fHFE is overexpressed. Change in the x intercept indicates that TfR numbers increase from 1.82 × 105 TfRs/tet+ cell to 2.77 × 105 TfRs/tet- cell. Linear regression was determined in the Cricket Graph program using r2 values. These results are representative of three experiments performed with triplicate data points without significant variation between experiments.

Early Association of HFE and TfR-- fHFE associates with TfR at the cell surface in a manner that lowers the affinity of Tf for TfR (Ref. 8 and this study). To investigate where this association occurs in the biosynthetic pathway, we tracked the synthesis and association of fHFE and TfR via endo H and pulse-chase analysis in fWTHFE/tTA HeLa cells (Fig. 3). Endo H is an endoglycosidase that cleaves between the proximal GlcNAc residues of high mannose and hybrid, but not complex N-linked, oligosaccharides. Loss of endo H sensitivity indicates that the protein has exited the endoplasmic reticulum and the cis-Golgi region of the biosynthetic pathway in pulse-chase experiments. The peptide sequence of HFE has three consensus sites for glycosylation at amino acids 110, 130, and 234. Immunoprecipitation of fHFE shortly after synthesis indicated little association between HFE and TfR (Fig. 3, 0 min chase). TfR was capable of coprecipitating with HFE within 30 min of chase when a significant portion of TfR was completely sensitive to endo H (Fig. 3, 30 min chase, lower bands of doublet at ~87 kDa (-Endo H) and ~80 kDa (+Endo H)). Thus, HFE can associate with TfR in the endoplasmic reticulum/cis-Golgi compartments. Between 30 and 120 min of chase, the amount of TfR that coprecipitated with HFE did not change, indicating that HFE does not gain any more ability to bind HFE over this period of time. In addition, within the first 120 min of chase, most of the HFE was rapidly degraded in that the levels of HFE decrease 2.5-fold. PhosphorImager analysis of the amount of TfR that immunoprecipitated with HFE (taking into consideration the relative abundance of Met in each protein) indicated that after an overnight label, the ratio of TfR to HFE was 1.7:1.


View larger version (76K):
[in this window]
[in a new window]
 
Fig. 3.   Early association of HFE and TfR. ~8.4 × 105 cells expressing fHFE were labeled for 10 min with 100 µCi of [35S]methionine and chased with complete medium for 30-min increments between 0 and 120 min. Alternately, cells were labeled for ~18 h (O/N) with 10 µCi of [35S]methionine. fHFE immunoprecipitated with anti-FLAG antibody was run on a 10% denaturing acrylamide gel under reducing conditions. TfR co-immunoprecipitated with fHFE within 30 min of synthesis and before it had become completely glycosylated. endo H cleaved oligosaccharides from high mannose and hybrid N-linked oligosaccharides. Loss of endo H sensitivity at any glycosylation site on the protein indicated that it had exited the cis-Golgi region. These results are representative of four experiments without significant variation between experiments.

HFE Associated with TfR Is More Stable-- The relative stabilities of HFE and TfR were compared over 8 h (Fig. 4, A and B) to further investigate the turnover of free and complexed HFE. Cells were fully induced to express fHFE by withdrawal of tetracycline from the medium for at least 3 days. Quantitation of the absolute amount of fHFE synthesized indicated that initially four times more fHFE was synthesized than TfR (Fig. 4, A and C, 0 chase after 1-h label). fHFE was rapidly degraded in the first 4 h of pulse-chase (Fig. 4, A and B). Degradation continued at a slower rate over the next 4 h, whereas the amount of TfR that co-immunoprecipitated with fHFE was unchanged (Fig. 4B). The 35S quantitation shown here is specific to the experiment shown and is representative of several experiments.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 4.   HFE steady-state levels are reduced to TfR-associated pool. ~1 × 106 cells expressing fHFE were labeled for 1 h with 100 µCi of [35S]methionine and chased with complete medium in 2-h increments for up to 8 h. Immunoprecipitates (IP) were run on 10% denaturing acrylamide gels under reducing conditions. A, lysates immunoprecipitated with anti-FLAG antibodies. Despite significant degradation of fHFE after the first 4 h of synthesis, the amount of TfR that co-immunoprecipitated remained unchanged. B, quantitation of fHFE (black bars) and TfR (white bars) co-immunoprecipitated with anti-FLAG antibody against fHFE. C, lysates immunoprecipitated with anti-TfR antibody 4091. TfR and fHFE levels did not change significantly over the 8-h time course. D, quantitation of fHFE (black bars) and TfR (white bars) co-immunoprecipitated with antibody 4091 against TfR. These results are representative of four experiments without significant variation between experiments.

TfR immunoprecipitation showed constant levels of TfR for 8 h (Fig. 4C). Previous studies indicated that the half-life of the TfR in the absence of HFE is ~24 h (21, 22). Surprisingly, fHFE levels co-immunoprecipitating with TfR were virtually unchanged over this time course (Fig. 4D). Quantitation of the relative amounts of fHFE and TfR demonstrated that one HFE bound per TfR dimer (Fig. 4D), consistent with earlier reports (6). These experiments indicate that when more HFE is synthesized than TfR, HFE is rapidly degraded, whereas the complex between TfR and HFE is stable. Two possibilities could account for these results. beta 2-Microglobulin might be limiting in this system. In this case, if HFE did not complex with beta 2-microglobulin, it would be rapidly degraded. Alternatively, TfR might stabilize the HFE·beta 2-microglobulin complex.

HFE Recognizes a Site on TfR Other than That of Tf-- The close association of fHFE and TfR over time and the lowered affinity of Tf for TfR in fHFE-expressing cells led us to investigate whether HFE has the same TfR-binding site as Tf. Earlier studies examining the association of Tf and TfR indicated that the unglycosylated form of TfR does not fold correctly and does not bind Tf (23-25). We investigated whether Asn-linked glycosylation was necessary for the association of fHFE with TfR. tet+ and tet- fWTHFE/tTA HeLa cells were treated with tunicamycin to inhibit Asn-linked glycosylation. Western blotting showed co-immunoprecipitation of unglycosylated TfR (~80 kDa) with HFE (Fig. 5, eighth lane, arrow). The discrepancy in the amount of unglycosylated TfR in tet+ and tet- cells immunoprecipitated with sheep anti-hTfR serum was due to the total amount of TfR in the cell. Unglycosylated TfR from tet+ cells is detectable at a longer exposure (data not shown). Since TfR co-immunoprecipitation with HFE is independent of glycosylation, the structural elements necessary for fHFE binding to TfR are different than for Tf binding to TfR.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 5.   TfR co-immunoprecipitation with HFE in tunicamycin-treated cells. ~7 × 105 cells treated overnight with 5 µg/ml tunicamycin (tuni) or mock-treated with 0.05% Me2SO were immunoprecipitated (IP) with sheep anti-hTfR or anti-FLAG antibody. The immunoprecipitates were subjected to SDS-PAGE on a 10% denaturing acrylamide gel under reducing conditions, transferred to nitrocellulose, and probed with anti-TfR antibody. The arrow indicates unglycosylated TfR co-immunoprecipitated with fHFE. These results are representative of three experiments without significant variation between experiments.

To confirm that HFE does not exclude Tf from the binding site of TfR, cell lysates of ~1 × 106 cells grown in tet+ or tet- medium were precipitated with Tf-agarose and analyzed by Western blotting as described under "Experimental Procedures." Simultaneous isolation of fHFE with TfR on Tf-agarose (Fig. 6) confirmed that HFE recognizes a site on TfR other than that of Tf.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 6.   HFE precipitates with Tf·TfR complex. Lysates from ~5 × 105 tet+ or tet- cells were allowed to bind Tf-conjugated agarose for 1 h at 4 °C. Pellets were washed, eluted, and subjected to SDS-PAGE on a 12% denaturing acrylamide gel under reducing conditions, transferred to nitrocellulose, and detected with sheep anti-hTfR and mouse anti-FLAG antibodies with the appropriate horseradish peroxidase-conjugated secondary antibody. Chemiluminescence detected ~94- and ~43-kDa species, providing further evidence for a binding site for HFE outside the Tf-binding site on TfR.

HFE Co-localizes with TfR-- Immunocytochemical staining of fHFE and TfR was performed to determine their intracellular localization. HFE synthesis was turned off in fWTHFE/tTA HeLa cells grown in the presence of tetracycline (tet+). Immunocytochemical staining of TfR in cells grown for >2 weeks in tet+ medium exhibited punctate cytoplasmic staining and localization to a perinuclear compartment (Fig. 7A). TfR is a marker for recycling endosomes, as 75-80% of TfR recycles through the endosomes, whereas only 20-25% is found on the surface at any point in time (26). fHFE levels were undetectable in cells maintained in tet+ medium (Fig. 7B). The staining pattern of TfR did not change in fWTHFE/tTA HeLa cells induced for fHFE expression (Fig. 7C). fHFE localized to the same perinuclear compartment (Fig. 7D) and exhibited complete co-localization with TfR. These results demonstrate that HFE does not drastically alter the distribution of TfR.


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 7.   Co-localization of fHFE with TfR in fWTHFE/tTA HeLa cells. A, permeabilized tet+ cells stained with mouse anti-hTfR (4093) and FITC-labeled anti-mouse antibodies show predominant TfR localization in a perinuclear compartment, with some at the cell surface. B, permeabilized tet+ cells stained with rabbit anti-HFE (CT1) and tetramethylrhodamine isothiocyanate-labeled anti-rabbit antibodies show no specificity for HFE, as tetracycline turns off expression of HFE and HeLa cells do not express endogenous HFE. C, permeabilized tet- cells stained with mouse anti-hTfR (4093) and FITC-labeled anti-mouse antibodies show no change in TfR localization despite fHFE expression in these cells. D, permeabilized tet- cells stained with rabbit anti-HFE (CT1) and tetramethylrhodamine isothiocyanate-labeled anti-rabbit antibodies show that fHFE localizes to the same intracellular compartment as TfR, with small amounts on the cell surface. E, permeabilized cells with decreased fHFE expression (i.e. passaged for 18 h in tetracycline) stained with antibody CT1 and tetramethylrhodamine isothiocyanate-labeled anti-rabbit antibody show a staining pattern identical to cells in D. These results are representative of four experiments without significant variation between experiments.

To confirm that the staining pattern we have seen is intrinsic to HFE and is not a result of accumulation of HFE in the biosynthetic pathway, fWTHFE/tTA HeLa cells were grown for 48 h in tet- medium and then for 18 h in tet+ medium to regulate the expression levels of HFE by turning off the promoter. Addition of tetracycline shuts off transcription almost immediately (18). Staining for fHFE was essentially identical to cells maintained in tet- medium (Fig. 7F). At the time of immunostaining, fHFE levels were decreased, but staining was still very distinct, in the same perinuclear compartment. Thus, the perinuclear staining of fHFE does not appear to be due to the transient passage through the biosynthetic pathway, but rather its intracellular localization at steady state.

HFE Co-localizes with Tf-positive Vesicles-- To determine whether fHFE co-internalizes with TfR, fWTHFE/tTA HeLa cells were allowed to take up Texas Red-labeled Tf for 30 min at 37 °C. The cells were washed with PBS, fixed, and stained as described under "Experimental Procedures." tet+ cells showed co-localization of TfR and Tf (Fig. 8, A and B, respectively). TfR and Tf co-localization was not changed in cells expressing fHFE (Fig. 8, C and D, respectively). tet- cells also exhibited co-localization of fHFE and Tf (Fig. 8, E and F, respectively). Combined with results from Fig. 7, Tf, TfR, and HFE all appear to traffic through the same endocytic perinuclear compartment.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 8.   HFE localizes to same compartment as Tf. A, permeabilized tet+ cells stained with mouse anti-hTfR (4093) and FITC-labeled anti-mouse antibodies show TfR localization at the cell surface and in a perinuclear compartment. B, Texas Red-labeled Tf localizes to the same internal compartment as TfR in tet+ cells. C, permeabilized tet- cells stained with mouse anti-hTfR (4093) and FITC-labeled anti-mouse antibodies show that TfR localization does not change with induction of HFE. D, Texas Red-labeled Tf continues to traffic through the same TfR-labeled perinuclear compartment despite fHFE expression. E, permeabilized tet- cells stained with mouse anti-FLAG (M2) and FITC-labeled anti-mouse antibodies show fHFE localization at the cell surface and in the same perinuclear compartment as TfR. F, Texas Red-labeled Tf localizes to the same perinuclear compartment as in C-E. TfR, Tf, and fHFE occupy the same compartment in tet- fWTHFE/tTA HeLa cells. These results are representative of three experiments without significant variation between experiments.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

To continue to define the relationship among iron, Tf, TfR, and HFE, we have investigated the biosynthesis and trafficking of fHFE in relation to TfR and have shown that HFE may regulate intracellular iron levels since its expression greatly decreases the levels of ferritin and modestly increases the levels of TfR. Both Ft and TfR are encoded by mRNAs containing iron response elements in their untranslated regions (for a review, see Ref. 27). TfR mRNA is stabilized by iron regulatory protein binding in a low cytoplasmic iron environment, whereas the translation of Ft mRNA is blocked. Modulation of TfR and Ft by HFE in this manner implicates HFE in the regulation of intracellular iron load.

Scatchard analysis of 125I-Tf binding to tet+ and tet- cell lines shows that Tf-binding sites increase from 1.8 × 105/uninduced cell to 2.8 × 105/induced cell, confirming the elevated level of TfR seen on Western blotting. The Scatchard data also show that fHFE decreases TfR affinity for Tf as seen in the increase in Kd from 1.2 to 11 nM. This is comparable to the 5-75 nM increase in Kd upon addition of 1 mM soluble HFE·beta 2-microglobulin heterodimer to HeLa cells reported earlier (8). The previous report showed no significant increase in TfR number because HeLa cells were only exposed to soluble HFE for the length of the experiment, not for days in culture as in the experiments reported here. The tetracycline-repressible system has the added benefit of comparing HFE-positive and -negative states within the same clonal cell line, circumventing discrepancies that may arise due to clonal variation.

Our studies on the synthesis of fHFE and TfR and susceptibility to endo H digestion demonstrate that these proteins are capable of associating with each other within 30 min of synthesis while the proteins are in the endoplasmic reticulum/cis-Golgi compartment. The pulse-chase analysis also indicated that a significant amount of fHFE is degraded between 90 and 120 min, the remainder of which is further processed by addition of complex carbohydrates less sensitive to endo H digestion. This pool of higher molecular mass fHFE is protected from degradation by its association with TfR and/or beta 2-microglobulin.

The kinetics of degradation of the fHFE pool associated with TfR are much slower than the degradation rate of the non-TfR-associated pool. Approximately 50% of the fHFE expressed in our system was degraded within 4 h of synthesis, whereas the amount of TfR remained steady. The pool of fHFE that associated with the TfR, however, did not change significantly over the course of 8 h. These results suggest that the complex is much more stable than HFE alone. Quantitation of the steady-state amount of fHFE co-immunoprecipitated with TfR yielded a stoichiometry of two TfRs for every fHFE, or one transferrin receptor dimer for every fHFE. The same stoichiometry has been reported by Lebron et al. (6) using gel filtration.

Not only does HFE have a different stoichiometry of binding to TfR, but it binds to a different region of TfR than Tf. Tunicamycin-treated tet- fWTHFE/tTA HeLa cells are capable of associating unglycosylated TfR and fHFE, as shown by the co-immunoprecipitation of TfR with fHFE. Tf binding to TfR is glycosylation-dependent because Tf does not show measurable binding to unglycosylated TfR (23, 24). Tf and HFE binding is not mutually exclusive since fHFE coprecipitates with TfR bound to Tf-agarose. The original observation (8) that HFE decreases Tf binding affinity for TfR, but not the number of binding sites, is also in agreement with the present results.

Immunocytochemical staining of fHFE in tet- fWTHFE/tTA HeLa cells is punctate and perinuclear and exhibits co-localization with TfR. The pattern is similar to TfR immunostaining in tet+ fWTHFE/tTA HeLa cells that do not express fHFE. These results show that HFE does not drastically alter the trafficking of TfR. TfR is, traditionally, an excellent marker for recycling endosomes. Once a clathrin-coated vesicle containing TfR pinches off the plasma membrane, it loses its clathrin coat and lowers its internal pH. In these low pH endosomes, iron is released from Tf. TfR and apotransferrin remain bound to each other and recycle to the cell surface. At neutral pH, apotransferrin is released, and TfR is free to bind more diferric Tf (for further discussion, see review in Ref. 28). HFE has no identifiable internalization motif in its cytoplasmic domain, yet fHFE co-localizes with Tf and TfR in perinuclear and cytoplasmic intracellular vesicles. The intracellular location of HFE may therefore be dependent on its association and endocytosis with TfR. The co-trafficking of HFE and TfR into endocytic compartments suggests that HFE may alter iron uptake inside the cell.

In this report, we conclude that TfR and HFE co-localize to endocytic compartments in a pattern typical of TfR. This finding is important in that it indicates that the function of HFE may not be limited to its alteration of the Tf-TfR interaction on the cell surface, but that HFE may also play a role in the cellular uptake of iron from the endosome. The expression of HFE in HeLa cells results in lower intracellular iron levels as reflected by the specific alteration of TfR and Ft levels in cells expressing fHFE. fHFE localization to Tf-positive vesicles suggests that regulation of internal iron stores by HFE may occur within the endosome.

Hereditary hemochromatosis is a disease characterized by an increase in the set point for bodily iron load. Hereditary hemochromatosis patients have elevated levels of Tf iron saturation. The degree of Tf saturation is an indicator of bodily iron load. The association of HFE with Tf may be critical for its role as a sensor of bodily iron load. With the expanding knowledge of novel functions of nonclassical MHC class I molecules, HFE has the potential to regulate iron homeostasis in a number of ways. HFE may act by itself, regulate other proteins involved in iron metabolism, or regulate the level of iron transport through the endosomal membrane or alter the kinetics of TfR cycling in a subtle manner. It will be important to characterize differences between regulation of Tf and iron uptake at the cellular level and in organs such as the liver, pancreas, pituitary, and heart that are damaged by iron overload in hereditary hemochromatosis patients. It will also be important to compare such regulation with what occurs in the cells of the intestinal mucosa that are anomalously iron-depleted in hemochromatosis patients.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant DK 40608.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by NHLBI Training Program in Molecular Hematology Grant T32-HL00781 from the National Institutes of Health.

parallel To whom correspondence should be addressed: Dept. of Cell and Developmental Biology, L215, Oregon Health Sciences University, Portland, OR 97201-3098. Tel.: 503-494-5845; Fax: 503-494-4253; E-mail: ennsca{at}ohsu.edu.

The abbreviations used are: MHC, major histocompatibility complex; Tf, transferrin; TfR, transferrin receptor; hTfR, human TfR; fHFE, FLAG epitope-tagged HFE; PAGE, polyacrylamide gel electrophoresis; tet, tetracycline; PBS, phosphate-buffered saline; endo H, endo-beta -N-acetylglucosaminidase HFITC, fluorescein isothiocyanateFt, ferritin.
    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Baron, U., Freundlieb, S., Gossen, M., and Bujard, H. (1995) Nucleic Acids Res. 23, 3605-3606[Medline] [Order article via Infotrieve]
  2. Bothwell, T. H., Charlton, R. W., and Motulsky, A. G. (1995) in The Metabolic and Molecular Basis of Inherited Disease (Scriver, C. R., Beudet, A. L., Sly, W. S., and Valle, D., eds), 7th Ed., Vol. II, pp. 1433-1462, McGraw-Hill Inc., New York
  3. Bonkovsky, H. L., Ponka, P., Bacon, B. R., Drysdale, J., Grace, N. D., and Tavill, A. S. (1996) Hepatology 24, 718-729[Medline] [Order article via Infotrieve]
  4. Powell, L. W., Campbell, C. B., and Wilson, E. (1970) Gut 11, 727-731[Medline] [Order article via Infotrieve]
  5. Feder, J. N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D. A., Basava, A., Dormishian, F., Domingo, R. J., Ellis, M. C., Fullan, A., Hinton, L. M., Jones, N. L., Kimmel, B. E., Kronmal, G. S., Lauer, P., Lee, V. K., Loeb, D. B., Mapa, F. A., McClelland, E., Meyer, N. C., Mintier, G. A., Moeller, N., Moore, T. E. M., Prasss, C. E., Quintana, L., Starnes, S. M., Schatzman, R. C., and Wolff, R. R. (1996) Nat. Genet. 13, 399-408[Medline] [Order article via Infotrieve]
  6. Lebron, J. A., Bennett, M. J., Vaughn, D. E., Chirino, A. J., Snow, P. M., Mintier, G. A., Feder, J. N., and Bjorkman, P. J. (1998) Cell 93, 111-123[Medline] [Order article via Infotrieve]
  7. Parkkila, S., Waheed, A., Britton, R. S., Bacon, B. R., Zhou, X. Y., Tomatsu, S., Fleming, R. E., and Sly, W. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13198-13202[Abstract/Free Full Text]
  8. Feder, J. N., Penny, D. M., Irrinki, A., Lee, V. K., Lebron, J. A., Watson, N., Tsuchihashi, Z., Sigal, E., Bjorkman, P. J., and Schatzman, R. C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1472-1477[Abstract/Free Full Text]
  9. Fehlmann, M., Peyron, J. F., Samson, M., Van Obberghen, E., Brandenburg, D., and Brossette, N. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 8634-8637[Abstract]
  10. Phillips, M. L., Moule, M. L., Delovitch, T. L., and Yip, C. C. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 3474-3478[Abstract]
  11. Due, C., Simonsen, M., and Olsson, L. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 6007-6011[Abstract]
  12. Verland, S., Simonsen, M., Gammeltoft, S., Allen, H., Flavell, R. A., and Olsson, L. (1989) J. Immunol. 143, 945-951[Abstract/Free Full Text]
  13. Schreiber, A. B., Schlessinger, J., and Edidin, M. (1984) J. Cell Biol. 98, 725-731[Abstract]
  14. Ghetie, V., and Ward, E. S. (1997) Immunol. Today 18, 592-598[CrossRef][Medline] [Order article via Infotrieve], and references therein
  15. Parkkila, S., Waheed, A., Britton, R. S., Feder, J. N., Tsuchihashi, Z., Schatzman, R. C., Bacon, B. R., and Sly, W. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2534-2539[Abstract/Free Full Text]
  16. Anderson, G. J., Powell, L. W., and Halliday, J. W. (1990) Gastroenterology 98, 576-585[Medline] [Order article via Infotrieve]
  17. Feder, J. N., Tsuchihashi, Z., Irrinki, A., Lee, V. K., Mapa, F. A., Morikang, E., Prass, C. E., Starnes, S. M., Wolff, R. K., Parkkila, S., Sly, W. S., and Schatzman, R. C. (1997) J. Biol. Chem. 272, 14025-14028[Abstract/Free Full Text]
  18. Gossen, M., and Bujard, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5547-5551[Abstract]
  19. Warren, R. A., Green, F. A., and Enns, C. A. (1997) J. Biol. Chem. 272, 2116-2121[Abstract/Free Full Text]
  20. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  21. Rutledge, E. A., Mikoryak, C. A., and Draper, R. K. (1991) J. Biol. Chem. 266, 21125-21130[Abstract/Free Full Text]
  22. Rutledge, E. A., Root, B. J., Lucas, J. J., and Enns, C. A. (1994) Blood 83, 580-586[Abstract/Free Full Text]
  23. Reckhow, C. L., and Enns, C. A. (1988) J. Biol. Chem. 263, 7297-7301[Abstract/Free Full Text]
  24. Williams, A. M., and Enns, C. A. (1991) J. Biol. Chem. 266, 17648-17654[Abstract/Free Full Text]
  25. Yang, B., Hoe, M. H., Black, P., and Hunt, R. C. (1993) J. Biol. Chem. 268, 7435-7441[Abstract/Free Full Text]
  26. Williams, A. M., and Enns, C. A. (1993) J. Biol. Chem. 268, 12780-12786[Abstract/Free Full Text]
  27. Klausner, R. D., Rouault, T. A., and Harford, J. B. (1993) Cell 72, 19-28[Medline] [Order article via Infotrieve]
  28. Enns, C. A., Rutledge, E. A., and Williams, A. M. (1996) Biomembranes 4, 255-287


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.